Search research articles
Contact Us
Filters
Showing results (11-20 of 82) with videos related to
Page
of 9
Sort By:
Health Affairs (Project Hope)
|
February 1, 2021
Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding
Jonathan J Darrow, Donald W Light
Yale Journal of Health Policy, Law, and Ethics
|
September 4, 2015
Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?
Aaron S Kesselheim, Jonathan J Darrow
Open Forum Infectious Diseases
|
February 5, 2020
Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?
Jonathan J Darrow, Aaron S Kesselheim
The New England Journal of Medicine
|
June 26, 2014
Drug development and FDA approval, 1938-2013
Jonathan J Darrow, Aaron S Kesselheim
Healthcare Policy = Politiques De Sante
|
June 16, 2020
Commentary: Expedited Regulatory Review of Low-Value Drugs
Jonathan J Darrow, Reed F Beall
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
July 21, 2018
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy
Frazer A Tessema, Jonathan J Darrow
Food and Drug Law Journal
|
August 26, 2015
A New Wave of Vaccines for Non-Communicable Diseases: What Are the Regulatory Challenges?
Jonathan J Darrow, Aaron S Kesselheim
JAMA Internal Medicine
|
May 17, 2021
Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling
Bishal Gyawali, Jonathan J Darrow, Aaron S Kesselheim
JAMA
|
January 15, 2020
FDA Approval and Regulation of Pharmaceuticals, 1983-2018
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
American Journal of Law & Medicine
|
September 16, 2025
Statutory Thickets and Drug Shortages: Accumulating Legislation as an Underlying Cause
Jonathan J Darrow, Erin R Fox, Timo Minssen
Page
of 9
Search research articles
Search
Showing results (11-20 of 82) with videos related to
Sort By:
Page
of 9
Health Affairs (Project Hope)
|
February 1, 2021
Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding
Jonathan J Darrow, Donald W Light
Yale Journal of Health Policy, Law, and Ethics
|
September 4, 2015
Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?
Aaron S Kesselheim, Jonathan J Darrow
Open Forum Infectious Diseases
|
February 5, 2020
Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?
Jonathan J Darrow, Aaron S Kesselheim
The New England Journal of Medicine
|
June 26, 2014
Drug development and FDA approval, 1938-2013
Jonathan J Darrow, Aaron S Kesselheim
Healthcare Policy = Politiques De Sante
|
June 16, 2020
Commentary: Expedited Regulatory Review of Low-Value Drugs
Jonathan J Darrow, Reed F Beall
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
July 21, 2018
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy
Frazer A Tessema, Jonathan J Darrow
Food and Drug Law Journal
|
August 26, 2015
A New Wave of Vaccines for Non-Communicable Diseases: What Are the Regulatory Challenges?
Jonathan J Darrow, Aaron S Kesselheim
JAMA Internal Medicine
|
May 17, 2021
Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling
Bishal Gyawali, Jonathan J Darrow, Aaron S Kesselheim
JAMA
|
January 15, 2020
FDA Approval and Regulation of Pharmaceuticals, 1983-2018
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
American Journal of Law & Medicine
|
September 16, 2025
Statutory Thickets and Drug Shortages: Accumulating Legislation as an Underlying Cause
Jonathan J Darrow, Erin R Fox, Timo Minssen
Page
of 9